Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 Diabetes​Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 Diabetes 

This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor agonists. ​This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor Read More

Popularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests study​Popularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests study 

A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance. ​A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less Read More

Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases​Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases 

This qualitative study assesses the quality, amount of active ingredient, and characteristics associated with counterfeiting of semaglutide purchased from illegal online pharmacies without a prescription. ​This qualitative study assesses the quality, amount of active ingredient, and characteristics associated with counterfeiting of semaglutide purchased from illegal online pharmacies without a prescription. 

Study indicates surge in GLP-1RA prescriptions to treat obesity and prevent its complications​Study indicates surge in GLP-1RA prescriptions to treat obesity and prevent its complications 

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States. ​Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like Read More

Semaglutide leads to greater weight loss in women than men with HF and improves HF symptoms​Semaglutide leads to greater weight loss in women than men with HF and improves HF symptoms 

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men. ​Semaglutide, a medication initially developed for type 2 diabetes and obesity, Read More